ZimVie Inc. (ZIMV) has entered into a definitive agreement to be acquired by an affiliate of ARCHIMED, a healthcare-focused investment firm.
Under the merger terms, ZimVie stockholders will receive $19.00 in cash for each outstanding share, reflecting an enterprise value of approximately $730 million.
The deal is expected to close by year-end 2025, after which ZimVie will become a privately held company and its shares will be delisted.
“This transaction marks a new chapter for ZimVie and underscores the value our team has built over the past several years,” said Vafa Jamali, Chairman of the Board and Chief Executive Officer.
